編集者への手紙：個別化抗血小板療法におけるCYP2C19薬理遺伝学的テストの実現可能性を称賛する—洞察と視点

Yi Cai（Sun）がこの問題を研究した。

www.synapsesocial.com/papers/69a76143c6e9836116a2f09e — DOI: https://doi.org/10.1016/j.clinthera.2026.01.008

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy· 2021 · 163 citations
2. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events· 2008 · 1,725 citations
3. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”· 2010 · 357 citations
4. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study